Background: There is limited head-to-head data on long-term safety and efficacy outcomes for everolimus-eluting stent (EES) and sirolimus-eluting stent (SES). Methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with Clinical Outcome) IV trial we prospectively randomized 2,774 patients. The SORT OUT IV trial demonstrated non-inferiority of the EES to the SES at 9 months. Followup through 5 years was complete in 2,770 (99.9%)). The 5-year pre-specified endpoint was a composite of safety and efficacy (major adverse cardiac event (MACE): cardiac death, myocardial infarction, target vessel revascularization and definite stent thrombosis). Results: At 4-year EES remained non-inferior to SES for the composite primary end point which occurred in 11.8% in the EES group and in 14.7% in the SES group (hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.65-0.98). Cardiac death 3.8% vs. 3.9% (HR 0.98, 95% CI 0.67-1.43) did not differ between the two groups, whereas target lesion revascularization (EES 4.2% vs. SES 6.2%, (HR 0.68, 95% CI 0.49-0.95) and myocardial infarction (EES 2.9% vs. SES 4.3%, (HR 0.67, 95% CI 0.45-1.00). Definite stent thrombosis were lower in the EES group (0.3%) compared to the SES group (2.0%) (HR¼0.15, 95% CI 0.05-0.45) which largely was attributable to a lower risk of very late definite stent thrombosis: 0.1% versus 1.3% (HR¼0.11, 95% CI 0.03-0.47). The 5-year results will be available for presentation at the TCT meeting 2014. Conclusions: At 4-year follow-up, MACE rate was significantly lower in EES treated patients compared to SES. The 5-year results will be available for presentation at the TCT meeting 2014.
Amphia Hospital Breda, Breda, NB Background: Drug-eluting stents with biodegradable polymers have been developed to address the risk of very late adverse events such as stent thrombosis. The purpose of this analysis was to compare incidence of stent thrombosis in an all-comers percutaneous coronary intervention (PCI) cohort treated with the biodegradable polymercoated biolimus-eluting stent (NoboriÔ; BES) or the durable polymer-coated everolimus-eluting stent (XienceÔ or PromusÔ; EES). Methods: The COMPARE II study is an open-label, prospective, randomized, noninferiority, all-comer trial undertaken at 12 sites across Europe currently at 3-year follow-up. Patients were randomly allocated (2:1) to receive either a BES or EES. Stent thrombosis was defined according to the Academic Research Consortium. Results: Of the 2707 study patients (4025 lesions), 2683 (99.1 %) completed 3 years follow-up. The 3-year stent thrombosis rates in the BES and EES group are tabulated.
Conclusions:
At 3-year follow-up the biodegradable polymer-coated BES has similar stent thrombosis rates as the durable polymer-coated EES without observing any tendency for reduction in frequency of this event beyond 1 year. In comparison to second-generation durable polymer coated DES, these results challenge the concept of biodegradable polymers. Background: There is limited head-to-head data on late stent-related outcomes for biolimus-eluting biodegradable (BES) polymer-coated Nobori stent and durable polymer-coated sirolimus-eluting stent (SES). Methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with Clinical Outcome) V trial we prospectively randomized 2468 patients. The SORT OUT V trial did not demonstrate non-inferiority of the BES to the SES at 9 months. Follow-up through 3 years is complete in 2467 (99.96%). The 3-year pre-specified endpoint was a composite of safety and efficacy (MACE: cardiac death, myocardial infarction and target vessel revascularization and definite stent thrombosis) and the safety endpoint of interest was definite stent thrombosis. Results: At 3-year MACE rate did not differ significantly between the two groups: BES group (10.1%) compared to the SES group (11.2%) (hazard ratio (OR) 0.90, 95% confidence interval (CI) 0.69-1.16). Definite stent thrombosis occurred within 3 years in 30 patients (1.2%). Overall rate of definite stent thrombosis did not differ significant between BES or SES treated patients (1.4% versus 1.0%, (OR¼1.33, 95% CI 0.64-2.81)).
At 3-year follow-up the Nobori stent with a biodegradable polymer was not associated with a lower risk of MACE or definite stent thrombosis compared to the Cypher stent with a durable polymer. However, the risk of stent thrombosis was timedependent. In the first year the risk was higher in the Nobori group. In the period from 2 to 3 year after implantation the risk was lower in the Nobori group
TCT-644
Stent thrombosis rates of the biodegradable polymer biolimus-eluting stent versus the durable polymer everolimus-eluting stent in all-comers undergoing PCI: A pooled analysis of the COMPARE II and NEXT trials at 1 year Kyoto University, Kyoto, Japan Background: Drug-eluting stents with biodegradable polymers have been developed to reduce the risk of very late adverse events such as stent thrombosis. Recent studies have indicated similar results with regard to safety outcomes for the biodegradable polymer-coated biolimus-eluting stent (NoboriÔ; BES) compared to the durable polymer-coated everolimus-eluting stent (XienceÔ or PromusÔ; EES) at 1 year. However, these trials were not powered to detect differences in low-frequency events such as stent thrombosis. Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned 5942 patients to BES or EES and is at present the largest pooled analysis of BES in all-comers requiring percutaneous coronary intervention (PCI). Here we conducted a patient level analysis at 1 year to assess rates of stent thrombosis defined according to the Academic Research Consortium. Results: The pooled unadjusted 1-year stent thrombosis rates of the 5942 study patients (8094 lesions) are tabulated. Covariate adjusted analyses accounting for baseline Background: Bioresorbable scaffolds (BVS) are a new treatment for coronary artery disease with promising results in first-in-man studies. As their use is extending in more complex lesions and populations, several cases of BVS thrombosis have been reported. We present optical coherence tomography findings from the culprit lesion of patients with BVS thrombosis. Methods: Up to 1/5/2014, 442 patients received BVS in our center. Among those, 14 patients that developed definite BVS thrombosis, according to the ARC criteria, were readmitted to our cathlab. Eight of them were imaged by optical coherence tomography (OCT) at the time of the event. OCT images were reviewed offline and the presence of thrombus, underexpansion, neointimal hyperplasia >50%, incomplete scaffold apposition, and scaffold discontinuity were assessed. The current status of dual antiplatelet therapy at the time of the event was also recorded. Results: Thrombus was visualized in 7/8 cases, underexpansion in 1/8, neointimal hyperplasia >50% in 2/8, incomplete scaffold apposition in 4/8, and scaffold discontinuity in 2/8 cases. In 3 cases, dual antiplatelet therapy had been discontinued at the time of the event. A summary of the most prominent OCT findings is presented in the Table. Conclusions: Discontinuation of antiplatelet therapy was identified in some patients as a reason for BVS thrombosis, however, in the majority of the cases mechanical factors were identified by OCT as a substrate. OCT can provide useful insights on the pathomechanisms of this complication. Results: 117 patients were included (54.4% drug-eluting stents). The median time after implantation was 3.5 years. ST was presented as ST-elevation myocardial infarction in 99 (84.1%) patients. Additional stent implantation was used in 54 patients (46.2%). Prior to intervention, there were no differences in LISA (71.4% vs. 63.0%; p¼0.33), aneurysm (11.1% vs. 11.1%; p¼1.0), underexpansion (31.7% vs. 18.5%; p¼0.10) or excessive neointimal proliferation (11.1% vs. 22.2%; p¼0.10) between patients treated with POBA vs. additional stent implantation. After PCI, persistent LISA was observed in 25.4% vs. 51.9% of patients (p¼0.01), respectively. Persistent underexpansion was observed in 6.3% and 14.8% (p¼0.05). Follow-up was obtained at 2.0 years. Cardiac death was observed in 3.4% vs. 5.8% of patients treated without and with additional stent (p¼0.55). Definite or probable re-thrombosis was observed in 1.7% vs. 7.7% (p¼0.13), respectively.
Conclusions:
The most frequent IVUS findings of late-ST are LISA and underexpansion. POBA seems to improve these IVUS-findings with respect to additional stent implantation. IVUS-guided treatment of definite ST is associated with favorable outcomes independently of the use of additional stent implantation.
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Predictors Background: Stent thrombosis (ST) has been described as a rare event in current drug-eluting stent (DES) era; however, its occurrence has been associated with high morbimortality, including fatality rates up to 50%. Previous studies have shown ST could be increased in complex subsets; however, the incidence and predictors of ST after DES overtime are still no fully understood Methods: A total of 5,408 pts with >8,000 coronary lesions undergoing routine or emergency PCI were prospectively (and consecutively) enrolled in the DESIRE (Drug-Eluting Stent In the REal World) registry at single institution between May/ 2002 and May/2012 (enrollment ongoing). By protocol, clinical follow-up was performed at 1 and 6 months, and yearly up to 12 years post-index procedure (97%). Stent thrombosis (ST) was defined according to the propositions of the Academic Research Consortium. Results: Mean age was 65 years, 32% had diabetes, and 16% had clinical presentation of recent myocardial infarction (MI) (< 30 days). Overall, patients were treated with approximately 8,500 DES and angiographic success was high (>99%) despite relatively high complexity in the majority of lesions (67% type B2/C). Up to 12 years (median 4.9 years) FU, cumulative incidence of ST was 2.4%, given that 95.1% of patients were ST-free at 10 years (Kaplan-Meier survival curve). Of the 113 ST reported, 13% occured up to 30 days, 55% were definite ST (ARC), and >60% occured 12 months. Independent predictors of ST are shown in the 
